# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Neutral.
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate o...
Leerink Partners analyst Daina Graybosch downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Outperform to Market Perform and...
Jones Trading analyst Soumit Roy downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Hold.
HC Wainwright & Co. analyst Edward White downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Neutral.